Data shows that about 1.6 million breast biopsies are performed each year
Washington D.C.: A recent study shows a multi-protein biomarker blood test to detect breast cancer can potentially reduce use of biopsy up to 67%.
Videssa Breast, a test put together by Provista Diagnostics, Inc, can help inform better decision-making after abnormal mammogram or other breast imaging results. The study, published in Clinical Breast Cancer, evaluated the performance of Videssa Breast among women under age 50.
With about 1.6 million breast biopsies performed each year, the implications of a blood test that can help clinicians confidently rule out breast cancer and avoid a potentially unnecessary biopsy are tremendous,” said Judith K Wolf, MD, Chief Medical Officer of Provista Diagnostics, Inc.
“We know imaging has limitations, especially among women under age 50 who, because of confounding factors, are more difficult to image. This research shows that Videssa Breast can be a powerful new tool in the diagnostic toolbox for clinicians.”
The study, A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years, demonstrated the performance of Videssa Breast from two prospective trials that enrolled 545 women, ages 25-50, with abnormal or difficult-to-interpret imaging (BI-RADS 3 and 4).
The overall performance of Videssa Breast in women with a breast cancer prevalence of 5.87%, resulted in a sensitivity of 87.5%, specificity of 83.8%, positive predictive value (PPV) of 25.2% and a negative predictive value (NPV) of 99.1%.
The study notes that the high NPV helps clinicians identify patients who are highly unlikely to have breast cancer. Depending on age, approximately 70 to 90% of breast biopsies are benign. The improved PPV of Videssa Breast over imaging — 25.2% vs. 8.8% — can increase the percentage of biopsies that yield a breast cancer diagnosis from one in 11 to one in four.
“When a mammogram yields an abnormal result, the challenge for every clinician is to decide which patients need follow-up, further imaging or biopsy,” said Josie R Alpers, MD, a radiologist specializing in mammography and diagnostic radiology at Avera McKennan Hospital & University Health Center and a study co-author.
“A test that is well-validated in a prospective trial means clinicians have a new way to accurately identify which patients may or may not need additional follow-up.”
Videssa Breast has been studied in two prospective, randomized, multi-centre and blinded clinical trials, in more than 1,350 patients ages 25-75.
It is the first prospective study of a proteomic assay composed of serum protein biomarkers and tumour-associated autoantibodies being used to detect breast cancer in women with abnormal imaging results.
The data featured in the current Clinical Breast Cancer publication is taken from the first study and cohort one of the second study.
Data from the over 50 cohort will be featured in upcoming publications. Videssa Breast is currently in limited clinical use through an early access programme.